FDA Orange Book · active-ingredient family
Sonrotoclax
Sonrotoclax is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:BEQALZI · NDA 220711
1
Brand (NDA)
0
Generics (ANDA)
1
Listed patents
0
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| BEQALZIRLD×4 | BEONE MEDICINES USA | NDA 220711 | — | May 13, 2026 |
Listed patents (1)
| Patent | Expires | In | Type |
|---|---|---|---|
| 11420968 | Apr 29, 2039 | in 13 yr 1 mo | SubstanceProduct |
Sonrotoclax — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
